Viewing Study NCT04746066



Ignite Creation Date: 2024-05-06 @ 3:46 PM
Last Modification Date: 2024-10-26 @ 1:56 PM
Study NCT ID: NCT04746066
Status: RECRUITING
Last Update Posted: 2022-05-05
First Post: 2021-02-02

Brief Title: Observational Study for Patients With Hemoglobinopathies and Rare Inherited Anemia and Covid 19
Sponsor: Società Italiana Talassemie ed Emoglobinopatie
Organization: Società Italiana Talassemie ed Emoglobinopatie

Study Overview

Official Title: Observational Study Multicentric Phamacological no Profit for the Treatment of Patients With Hemoglobinopathies and Rare Inherited Anemia Affected by Covid 19
Status: RECRUITING
Status Verified Date: 2022-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The COVID-19 pandemic is causing many deaths around the world putting a strain on health services Patients with pre-existing chronic conditions are most affected by the SARS-COV2 infection Infectious complications are a common cause of mortality and one of the main causes of morbidity in all these diseases The main objective of this project is the assessment of patients with thalassemia drepanocytosis other haemoglobinopathies and rares inherited anemias suffering from SARS-COV-2 to

1 Obtain clinical and epidemiological data that can provide information on a possible increased vulnerability of these patients to SARS-COV-2 infection
2 Sharing therapeutic approaches considering the lack of information about the treatment
Detailed Description: The COVID-19 pandemic is causing many deaths around the world putting a strain on health services Patients with pre-existing chronic diseases are most affected by SARS-COV2 infection Italy is one of the countries most involved Thalassaemia drepanocytosis other hemoglobinopathies and inherited anemias are widespread in italy and the mediterranean area Thalassaemia syndromes are characterized by different clinical forms with mutations in globin genes that cause the reduction or complete absence of synthesis of the globin chain Transfusion therapy remains the basis of thalassaemia management Based on the extent of the severity of anemia and clinical presentation thalassaemia was classified as transfusion-dependent TDT and non-transfusion-dependent NTDT Transfusion inevitably contributes to iron overload which is associated with secondary morbidity including organ damage especially heart liver bone tissue and endocrine glands In ntdt comorbility is mainly related to chronic anemia and increased gastrointestinal iron adsorption

Other inherited anaemias include a large group of pathologies such as hyporegenerative anaemias such as congenital diseritropoietic anaemia and diamond-blackfan anemia anaemies from deficiency of red blood cell membrane proteins due to altered membrane structure such as hereditary spherocytosis and hereditary ellipsocytosis and impaired membrane transport function such as hereditary stomatocytosis anaemies due to enzymatic deficiency the most frequent of which are pyruvate deficiency kinase and glucose-6 phosphate dehydrogenase sideroblastic anaemias and all other hereditary microcytic anaemies such as irida All these anemias are characterized by high phenotypic heterogeneity but in most cases chronic hemolytic anemia iron overload and addiction transfusion are found as a percentage of a variable of cases Transfusion therapy remains the basis of the management of these anaemias along with splenectomy not practicable in all these classes of anemia As with thalassaemia syndromes in such anaemias we find secondary morbidity such as heart liver and endocrine damage resulting from both chronic anemia and iron overload

Infectious complications are a common cause of mortality and one of the main causes of morbidity in all these pathologies The greater quantitative and functional quantities the involve t and b lymphocytes production of immunoglobulins neutrophils and macrophages chemotaxis and phagocytosis as well as the complement system Excess iron can alter the immune balance in favour of the growth of infectious organisms Other factors include multiple transfusions associated with constant allo-antigenic stimulation A large percentage of adult patients are splenectomized and risk complications related to splenectomy such as capsuled bacterial infections and immune system changes low levels of zinc another immune regulator iron chelation therapy which predisposes to serious yersinia-like infections The circulation of abnormal erythrocytes is the cause of another permanent immune stimulus In addition particularly in elderly patients the coexistence of adrenal hypofunction makes the response to sepsis less effective

However we have no information on the vulnerability of patients with thalassaemia drepanocytosis other hemoglobinopathies and hereditary anemias to SARS-COV2 infection In order to obtain more information useful to increase our knowledge a retrospective survey has been planned

The main objective of this project is the evaluation of patients with thalassaemia drepanocytosis other hereditary hemoglobinopathies and anaemias affected by SARS-COV2 to

1 obtain clinical and epidemiological data that may dare information on a possible increased vulnerability of these patients to SARS-COV2
2 share therapeutic approaches considering the lack of information about treatment

This is an italian study of observational pharmacological non-interventional retrospective prospective and multicenter non-profit cohort Patients diagnosed with thalassaemia drepanocytosis other hemoglobinopathies and hereditary anaemia positive to the SARS-COV2 virus will be enlisted Patient data from reference centers will be introduced into the card via a web service

The scientific committee of the project has discussed and approved a set of data that will be collected by local centers and that will feed the data collection database

The study will be launched in every Italian center that requires participation The Italian Society of Thalassaemia and Hemoglobinopathies SITE in its role as a scientific reporting company for pathology and the Foranemia Foundation a non-profit organization makes available to the center of microcitemie coordinator of the study a special web space for online data collection assuming the costs

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None